Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Growing focus on gene-based therapies, advances in editing tools, and increasing research investments are accelerating the adoption of genome editing technologies across life sciences and agriculture.

For the first time, the tools to rewrite human biology are moving from speculative fiction into regulated clinics and ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Genome Editing Market Genome Editing Market Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Global ...

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Powered by gene editing advances like CRISPR and base editing, cell and gene therapy (CGT) is delivering on the promise of genomic medicine. First-generation CAR T-cell therapies, for example, have ...

A generation ago, writing a piece like this about using artificial intelligence to develop genome-editing medicines would have sounded like a Star Trek plotline. But both fields have matured to the ...

One patient still in remission 3 years after single infusion of base-edited CAR7 T cells ...